Glioblastoma: pp65 Vaccine With High-dose Temozolomide May Improve Survival

Share this content:
With vaccine treatment, 4 patients had not progressed for more than 4.9 years and 3 patients had not progressed more than 7 years post-diagnosis.
With vaccine treatment, 4 patients had not progressed for more than 4.9 years and 3 patients had not progressed more than 7 years post-diagnosis.

Combining high-dose temozolomide chemotherapy with vaccination against cytomegalovirus (CMV) antigen pp65 was associated with surprisingly long survival times among patients with glioblastoma (GBM), according to a small phase 1 cohort study published in Clinical Cancer Research.1

When treated with concurrent temozolomide chemoradiation, GBM carries median survival of 14.6 months.

Although the phase 1 trial was not designed to assess treatment efficacy, combined vaccine-chemotherapy was associated with a median progression-free survival (PFS) of 25.3 months and a median overall survival time of 41.1 months.

Four patients had not progressed for more than 4.9 years and 3 patients had not progressed more than 7 years post-diagnosis.

Noting that CMV viral proteins are expressed in 90% of GBM tumors, the researchers used an anti-pp65 dendritic cell vaccine to make GBM cells recognizable to patients' immune cells.

Eleven study participants had newly diagnosed glioblastoma. They received dose-intense temozolomide with 3 or more vaccinations of pp65 dendritic cells mixed with adjuvant granulocyte macrophage colony-stimulating factor (GM-CSF).

After combined treatment, the proportion and proliferation of regulatory T cells (Tregs) climbed and remained elevated, the team reported. Adverse events included known temozolomide-related toxicities such as nausea, fatigue, thrombocytopenia, and pronounced lymphopenia. No treatment-limiting toxicities occurred.

RELATED: Phase 3 Trial: Vaccine Trial for Patients with Glioblastoma

“No known prognostic factors (age, Karnofsky performance status [KPS], IDH-1/2 mutation, and MGMT promoter methylation) predicted more favorable outcomes for the patients in this cohort,” the study authors reported.

References

  1. Batich KA, Reap EA, Archer GE, et al. Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. Clin Cancer Res. 2017 Apr 14. doi: 10.1158/1078-0432-CCR-16-2057 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters